A Real-world Study in Participants With Smoldering Multiple Myeloma
Smoldering Pathway Assessment Real-World Knowledge (SPARK) Study-Retrospective Observational, Non-interventional Chart Review Study in Smoldering Multiple Myeloma
Sponsor: Janssen-Cilag Ltd.
Listed as NCT06472778, this observational or N/A phase trial focuses on Smoldering Multiple Myeloma and remains ongoing. Sponsored by Janssen-Cilag Ltd., it has been updated 16 times since 2024, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
16 versions recorded-
Feb 2026 — Present [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Jan 2026 — Feb 2026 [monthly]
Recruiting
-
Nov 2025 — Jan 2026 [monthly]
Recruiting
-
Oct 2025 — Nov 2025 [monthly]
Recruiting
-
Sep 2025 — Oct 2025 [monthly]
Recruiting
▶ Show 11 earlier versions
-
Jun 2025 — Sep 2025 [monthly]
Recruiting
-
May 2025 — Jun 2025 [monthly]
Recruiting
-
Apr 2025 — May 2025 [monthly]
Recruiting
-
Mar 2025 — Apr 2025 [monthly]
Recruiting
-
Feb 2025 — Mar 2025 [monthly]
Recruiting
-
Jan 2025 — Feb 2025 [monthly]
Recruiting
-
Nov 2024 — Jan 2025 [monthly]
Recruiting
-
Oct 2024 — Nov 2024 [monthly]
Recruiting
-
Sep 2024 — Oct 2024 [monthly]
Recruiting
-
Aug 2024 — Sep 2024 [monthly]
Recruiting
-
Jul 2024 — Aug 2024 [monthly]
Recruiting
First recorded
May 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Janssen-Cilag Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .